1W Return
1M Return
6M Return
1Y Return
3Y Return
Start SIP in Alivus Life Sciences
Alivus Life Sciences Stock Performance
52 Week Low - High
Today’s Low - High
Open
Prev. Close
Total Traded Value
Alivus Life Sciences Fundamental
Market Cap (in crs)
Face Value
Turnover (in lacs)
Key Metrics
Qtr Change %
46.04% Gain from 52W Low
-4.5
Dividend yield 1yr %
0
Alivus Life Sciences Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
Current Price
5Day EMA
1,070.00
10Day EMA
1,048.60
12Day EMA
1,044.10
20Day EMA
1,036.20
26Day EMA
1,035.10
50Day EMA
1,039.80
100Day EMA
1,045.00
200Day EMA
1,014.00
5Day SMA
1,063.10
10Day SMA
1,037.20
20Day SMA
1,024.50
30Day SMA
1,035.80
50Day SMA
1,024.20
100Day SMA
1,051.30
150Day SMA
1,065.20
200Day SMA
1,050.80
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 78504 Rs | 137901 Rs |
Week Rs | 86428 Rs | 163411 Rs |
Month Rs | 51278 Rs | 106020 Rs |
Resistance & Support
1,093.50
Pivot
Resistance
First Resistance
1,123
Second Resistance
1,142
Third Resistance
1,171.50
Support
First Support
1,074.50
Second support
1,045
Third Support
1,026
Relative Strength Index
61.20
Money Flow Index
80.49
MACD
8.96
MACD Signal
-3.06
Average True Range
50.35
Average Directional Index
12.33
Rate of Change (21)
9.92
Rate of Change (125)
17.65
Similar stocks
Similar Stocks
Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
13,528.09 | 755.95 | 1335.1 | 1,090.70 | 7.38% | 2.11% | 7.45% | 33.19% | 132.27% | 2.05% | 30.45 | 40.76 | 5.30 | ||
14,281.84 | 1225 | 2641 | 1,869.00 | -0.48% | -6.05% | -5.08% | 38.52% | 166.74% | 0.27% | 44.38 | 40.76 | 9.33 | ||
11,055.14 | 389.35 | 721 | 455.60 | -6.01% | -6.28% | -17.84% | 7.68% | 61.75% | 0.33% | 34.21 | 40.76 | 3.44 | ||
14,304.34 | 617.05 | 1309.9 | 894.70 | -2.80% | 0.23% | -20.68% | 33.19% | 90.38% | 0.56% | 290.39 | 40.76 | 6.22 | ||
13,686.73 | 4902 | 10524.95 | 6,033.50 | -7.72% | 3.80% | -9.46% | -28.62% | -14.80% | 1.97% | 30.89 | 40.76 | 15.87 | ||
12,335.99 | 347.6 | 968.3 | 685.40 | -4.57% | -19.63% | 48.68% | 83.38% | 0.00% | 0.14% | 52.61 | 40.76 | 13.36 | ||
11,377.13 | 4211.55 | 5375 | 4,940.90 | 0.01% | 2.35% | 0.40% | 0.00% | 0.00% | 0.00% | 56.52 | 40.76 | 41.69 |
Alivus Life Sciences Company background
Founded in: 2011
Managing director: Yasir Yusufali Rawjee
Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited, on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited dated 10 August 2018. A shareholders resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business. The first product registered with USFDA in 2003. The Company acquired Glaxo SmithKlines (GSK) API manufacturing plant in Ankleshwar, Gujarat in 2003. It established manufacturing plant at Kurkumbh, Maharashtra in 2002. In 2004, it commenced manufacturing at Mohol, Maharashtra. In 2013, the Company commenced manufacturing at Dahej, Gujarat. The Company increased its API manufacturing capabilities by enhancing the existing production capacities at Ankleshwar Dahej facilities in FY 2023, by an aggregate annual total installed capacity of 640 KL.The Company expanded projects with additional 240 KL at Dahej in 2023. The brownfield expansion at Dahej for Oncology Plant was completed. Out of the 2 independent modules, one module commissioned 100%. 192 KL out of the 400 KL intermediate manufacturing block at Ankleshwar commissioned in 2023. The Company came up with an IPO of 21,022,222 Equity Shares comprising a Fresh Issue of 14,722,222 Equity Shares and Offer for Sale of 6,300,000 Equity Shares aggregating to Rs 1513.6 Crores in August, 2021.
Alivus Life Sciences FAQs
What is Share Price of Alivus Life Sciences ?
Alivus Life Sciences share price is ₹1087.7 in NSE and ₹1081.8 in BSE as on 30/4/2025.
How has Alivus Life Sciences shares performed in the past ?
Alivus Life Sciences share price in the past 1-year return was 33.18. The Alivus Life Sciences share hit a 1-year low of Rs. 755.95 and a 1-year high of Rs. 1335.1.
What is the market cap of Alivus Life Sciences ?
The market cap of Alivus Life Sciences is Rs. 13528.09 Cr. as of 30/4/2025.
What is the current P/E ratio of Alivus Life Sciences ?
The PE ratios of Alivus Life Sciences is 30.45 as of 30/4/2025.
What is the current PB ratio of Alivus Life Sciences ?
The PB ratios of Alivus Life Sciences is 5.29 as of 30/4/2025
What is the Mutual Fund shareholding in Alivus Life Sciences ?
The Mutual Fund Shareholding in Alivus Life Sciences was 3.59% at the end of 30/4/2025.
How to buy Alivus Life Sciences shares?
You can easily buy Alivus Life Sciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
Please be aware that Alivus Life Sciences stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account
